Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D70SHJ
|
|||
| Drug Name |
mRNA-2416
|
|||
| Synonyms |
mRNA-OX40L
Click to Show/Hide
|
|||
| Drug Type |
mRNA therapy
|
|||
| Indication | Lymphoma [ICD-11: 2A80-2A86; ICD-9: 202.8, 208.9] | Phase 1 | [1] | |
| Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 1 | [2] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | ||
| Company |
Moderna Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | TAX transcriptionally-activated glycoprotein 1 (OX40) | Target Info | Replacement | [3] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| TSLP Signaling Pathway | ||||
| Reactome | TNFs bind their physiological receptors | |||
| WikiPathways | Vitamin D Receptor Pathway | |||
| TSLP Signaling Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT03323398) Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies. U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of Moderna Therapeutics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.